Indeed, systemic neutralization of NKG2A has been shown to unleash a strong anti‐tumor response in mouse preclinical studies by increasing NK and/or CD8 T‐cell effector functions, which were further enhanced when combined with anti‐PD‐(L)1 therapy (Andre et al, 2018; van Montfoort et al, 2018). This evidence concerns the gene KLRC1 and neoplasm.